Onintza Sagredo - Concepedia

Author

Onintza Sagredo

Universidad Complutense de Madrid ORCID

Also Known As

Justo G. de Yébenes, O SAGREDO, O Sagredo, O. Sagredo, O.L. Gil de Sagredo, Onintza Sagredo

Publications

Citations

H-Index

Concepts

All Affiliations

Universidad Complutense de Madrid Biomedical Research Networking Center on Neurodegenerative Diseases Instituto Ramón y Cajal de Investigación Sanitaria Hospital Universitario Fundación Alcorcón Centro de Investigación Biomédica en Red

About

Onintza Sagredo is an author at Universidad Complutense de Madrid specializing in neuroscience, medicine, and social sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	979
2	Neuroscience	7	7	979
3	Social Sciences	5	5	763
4	Neurology	5	5	856
5	Health Sciences	1	1	83

Onintza Sagredo

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity Javier Palazuelos, Tania Aguado, M. Ruth Pazos, Brain Disease ExcitotoxicitySynaptic SignalingCannabinoid PharmacologyCannabinoid-derived DrugsSocial Sciences	2009	375
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease Cristina Blázquez, Anna Chiarlone, Onintza Sagredo, Brain	2010	195
Cannabinoid CB<sub>2</sub>receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease Onintza Sagredo, Sara González, Ilia Aroyo, Glia	2008	194
A restricted population of CB <sub>1</sub> cannabinoid receptors with neuroprotective activity Anna Chiarlone, Luigi Bellocchio, Cristina Blázquez, Proceedings of the National Academy of Sciences	2014	158
A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease José Luis López-Sendón, Juan García Caldentey, Patricia Trigo Cubillo, Journal of Neurology Neurodegenerative DiseasesNeuropsychologyHuntington ’Pilot TrialClinical Neurology	2016	151
Natural Cannabinoids Improve Dopamine Neurotransmission and Tau and Amyloid Pathology in a Mouse Model of Tauopathy Marı́a José Casarejos, Juan Perucho, Ana Gómez, Journal of Alzheimer s Disease	2013	146
Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acid<i>in vivo</i>by mechanisms independent of the activation of cannabinoid, vanilloid TRPV<sub>1</sub>and adenosine A<sub>2A</sub>receptors Onintza Sagredo, J.A. Ramos, Alessandra Decio, European Journal of Neuroscience	2007	145
Neuroprotective Properties of Cannabigerol in Huntington's Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice Sara Valdeolivas, Carmen Navarrete, Irene Cantarero, Neurotherapeutics MedicinePharmacologyNeuroprotective PropertiesR6/2 MiceNeuroprotection	2014	133
Neuroprotective effects of phytocannabinoid‐based medicines in experimental models of Huntington's disease Onintza Sagredo, M. Ruth Pazos, Valentina Satta, Journal of Neuroscience Research Phytocannabinoid‐based MedicinesExperimental ModelsCannabinoid PharmacologySocial SciencesOxidative Stress	2011	107
Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s Disease: Role of CB<sub>1</sub> and CB<sub>2</sub> Receptors Sara Valdeolivas, Valentina Satta, Roger G. Pertwee, ACS Chemical Neuroscience Cannabinoid PharmacologySocial SciencesOxidative StressMolecular PharmacologyNeurobiology Of Disease	2012	90

Page 1